Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) said on January 10, 2020, that it had received a proposal from a private equity fund interested in acquiring a majority or all of its outstanding shares, valuing the company at as much as $993 million. Sorrento said it was reviewing the non-binding proposal of up to $7 per Sorrento share.